Moderna mRNA supplier, Lonza, let's CEO go on concerns over earnings prospects

Let battle commence between the legal teams—who will pick up the tab for obsolescence?

Reuters reports

Pfizer’s trusty ‘fact checker’, Reuters, has just reported some incredibly significant news:

Lonza CEO departure prompts concern over earnings prospects

“Contract drug manufacturer Lonza (LONN.S) said on Monday Chief Executive Pierre-Alain Ruffieux will leave the Swiss company by mutual agreement at the end of the month, weighing on investor confidence about the group's medium-term profit prospects.